HIV Vaccines

The most important breakthroughs of the past century involved the development of vaccines to protect against viruses: smallpox, polio, hepatitis, human papillomavirus (HPV), and even chickenpox. But one virus remains elusive to those seeking to create a vaccine to guard against it: HIV. Getting vaccinated early, before sexual exposure, is also effective in preventing certain types of sexually transmitted infections (STIs). Vaccines are available to prevent human papillomavirus (HPV), hepatitis A and hepatitis B.

An HIV vaccine is a potential vaccine that could be either a preventive vaccine or a therapeutic vaccine, which means it would either protect individuals from being infected with HIV or treat HIV-infected individuals. It is thought that an HIV vaccine could either induce an immune response against HIV (active vaccination approach) or consist of preformed antibodies against HIV (passive vaccination approach). Two active vaccine regimens, studied in the RV 144 and Imbokodo trials, showed they can prevent HIV in some individuals. However, the protection was in relatively few individuals, and was not long lasting. For these reasons, no HIV vaccines have been licensed for the market yet.

    Related Conference of HIV Vaccines

    November 28-29, 2024

    6th World Congress on Vaccine and Immunology

    Paris, France
    December 05-06, 2024

    36th Annual Congress on Vaccine and Clinical Trials

    Vancouver, Canada
    February 27-28, 2025

    8th International Conference on Vaccines and Immunology

    Paris, France
    April 28-29, 2025

    2nd Global Summit on Vaccines & Emerging Diseases

    Bali, Indonesia

    HIV Vaccines Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in